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http://www.biomedcentral.com/1471-2288/12/103RESEARCH ARTICLE Open AccessWhat does a modified-Fibonacci dose-escalation
actually correspond to?
Nicolas Penel1,2* and Andrew Kramar1,2Abstract
Background: In most phase I oncology trials, it is often stated that the dose increments follow a “modified-
Fibonacci sequence”. This term, however, is vague.
Methods: To better characterize this sequence, we reviewed 81 phase I trials based on this concept.
Results: Out of 198 phase I oncology trials, 81 (41%) are based on modified-Fibonacci series. Actual incremental
ratios varied in a large range from 0.80 to 2.08. The median of actual increments was about 2.00, 1.50, 1.33, 1.33,
1.33, 1.33, 1.30, 1.35. . .. The “modified Fibonacci-sequence” gathers heterogeneous variation of the genuine
sequence, which does not tend to a constant number at higher dose-levels.
Conclusion: This confusing term should be avoided.
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Dose-finding phase I trials seek to determine an optimal
recommended dose for a new compound for further
testing in phase II trials [1,2]. For cytotoxic drugs, this
dose corresponds to the highest dose associated with an
acceptable level of toxicity, referred to as the maximal
tolerated dose (MTD). Such trials consist in a design
where successive cohorts of patients are treated with in-
creasing doses of the drug. The phase II recommended
dose is usually taken as the dose level just below the
MTD [1,2]. Endpoints other than the MTD have been
considered for molecular targeted therapies such as opti-
mal biological dose (OBD). Nevertheless, two different
notions are largely confounded: guidance for determin-
ing the actual dose levels to be explored in the trial and
guidance for the dose-escalation strategy between dose
levels, that is, the determination of the number of
patients enrolled at each dose level. Basically there are
two approaches for guiding the number of patients en-
rolled at each dose level: algorithm-based methods such
as the classical 3 + 3 and more recent model-based* Correspondence: n-penel@o-lambret.fr
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distribution, and reproduction in any mediummethods such as the different versions of the continual
reassessment method [1-3]. The guidance for determin-
ing which dose levels are to be explored is usually based
on pre-clinical and pharmacokinetic data. Once a start-
ing dose level has been determined, a Fibonacci se-
quence, or its modified version, is one of the most
frequently used methods for determining dose
increments.
The genuine and the modified Fibonacci sequence de-
termine dose steps (increments). The genuine Fibonacci
sequence is defined by the linear recurrence equation
Fn ¼ Fn1 þ Fn2 , which goes like this: 1, 2, 3, 5, 8, 13,
21, 34, 55, 89. . . In other words, the next number in the
sequence is equal to the sum of its two predecessors.
The ratio of successive Fibonacci numbers Fn/Fn-1 (in-
cremental ratio) tends rapidly to a constant ((1 + √5)/
2) 1.61) as n approaches infinity. For the purpose of a
dose-seeking phase I trial, this sequence offers very
appealing guidance for the increment set up; because
the absolute doses and the absolute dose change grow
larger and larger with constant incremental ratios
(1.61; +61%) [1,4,5]. The genuine Fibonacci sequence
in itself is not commonly used as guidance for establish-
ing dose increments in the trial. Phase I methodologists
refer commonly to the “so-called modified Fibonacci se-
quence” [5], which has the followng incremental ratios:ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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levels. In this form, the incremental ratio tends to a
smaller constant number: 1.33.
Given that the so-called modified Fibonacci sequence
remains the most popular dose increment determination
scheme, but is also a non-standardized method, we car-
ried out a literature review over a ten-year period of
published dose-finding phase I trials investigating one
drug to better characterize this series.
Methods
The reports, considered for the present study, were
extracted from a large database of 327 phase I trials (311
manuscripts) published between January 1997 and De-
cember 2008 in five major journals in the field of oncol-
ogy(Annals of Oncology, Clinical Cancer Research,
European Journal of Cancer, Investigational New Drugs
and Journal of Clinical Oncology; see Additional file 1).
We have used Pubmed-Medline and the following key-
words: “dose-seeking”, “phase 1 trial” and “cancer”. From
these 327 trials, 197 were single-agent dose-seeking
trials. From each report, we extracted the method used
for guiding the dose-escalation and the result of the trial.
“Failure of the trial” described a study failing to deter-
mine a phase-II-recommended-dose. The dose-
increment guidance was classified into five categories:
modified Fibonacci sequence, pharmacologically guided
method [6], constant ratio incremental >+2.0 (aggressive
increment, including most of accelerated titration
designs [7]), constant ratio incremental <1.33 (prudent
increment) and other methods (including bayesian
approaches [8]). Among studies which used a modified
Fibonacci sequence, we extracted the precise dose used
at each dose-level. By convention, we have considered
the actual dose by successive cohorts even if de-
escalation occurred or the sponsor decided to explore an
intermediate dose-level. De-escalation have been seen in
only two trials. We then calculated for every dose-level:
the mean dose administered at each dose level, itsFigure 1 Pattern of 327 dose-seeking phase I trials.standard derivation, the median and the range. We then
calculated the ratio of the median increments. For ex-
ample, the ratio of median increment at dose-level 3 was
the ratio of the median dose at level 3 over the median
dose at level 2 across the studies which included at least
these both dose-levels.
Lastly we plotted the mean incremental ratio (±95%
confidence interval) on the log scale for the trial data
compared to the incremental ratios of the genuine and
modified Fibonacci series.
Results
Figure 1 describes the pattern of studies. The modified-
Fibonacci-sequence was the most common method of
dose-escalation (92/197, 46%). The contemporary studies
still rarely used sophisticated designs such as Bayesian
and pharmacologically guided dose escalation (Table 1).
The median number of dose-levels explored was 5
(range, 2–12). Four studies actually investigated only 2
dose-levels (Table 2).
The term modified-Fibonacci-sequence covered a vast
range of actual doses (Table 2). For example, the actual
increment at the fifth dose-level varied from 1.20 to
6.00. For every dose-level the observed dispersion of the
actual increment was large (Table 2).
The actual sequences used in the trials differed from
the genuine Fibonacci sequence and the modified one by
several points. The median actual dose was far from the
genuine Fibonacci sequence, with values lower than
expected starting from the fifth dose-level (5.32 instead
of 8) and then huge differences in later dose-levels
(38.44 instead of 233 at the 12th dose-level, see Figure 2
and Table 2). The median of actual increments was
about 2.00, 1.50, 1.33, 1.33, 1.33, 1.33, 1.30, 1.35, 1.32,
1.24 and 1.25 (Table 3). This sequence did not tend to a
constant number (see 4th column of Table 3).
The mean incremental ratios followed the modified Fi-
bonacci series more closely than the genuine series and
they were statistically lower than the genuine series for
Table 1 Dose-escalation-methods and results of 198
single-agent dose-seeking phase I trials
Guidance for the number of
patients enrolled by dose-levels
Algorithm-based
methods (such as
3 + 3) n (%)
Model-based
methods (such






92 (46.4) 0 (0)
Fixed increment:
<+33%
28 (14.1) 0 (0)
Fixed increment:
>100%
62 (1.3) 1 (0)
PK-guided 3 (1.5) 1 (0)
Other 7 (3.5) 4 (2) Figure 2 Comparison between actual sequence, genuine
Fibonacci sequence and modified Fibonacci sequence.
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fied series for dose levels 2 to 5 (Figure 2). From dose
levels 8 onwards, the mean incremental ratios were con-
tained within the two series.
Moreover, in 13 studies (16%), at least one increment
was significantly higher (e.g. >50%) than the increment
planned with the modified-Fibonacci series.Discussion
Our analysis highlights the following facts. Most of con-
temporary dose-seeking phase I trials remain guided by
the “modified Fibonacci sequence” (about 50%, Table 1).
This term includes a vast variation in doses (from -20%
to +208.3%, Table 2). Moreover, the actual series does
not tend to a constant incremental ratio as expected
from the modified Fibonacci sequence (Table 2) TheTable 2 Dose and incremental ratios in 81 modified-Fibonacc
Planned dose in








3 (77) 3 3.3
4 (67) 5 5.1
5 (58) 8 6.60
6 (43) 13 8.80
7 (32) 21 11.8
8 (19) 34 15.6
9 (13) 55 20.8
10 (7) 89 27.8
11 (5) 144 36.8
12 (3) 233 49.0
13 (0) 377 65.2
n: number of studied reaching the specified dose-level; SD: standard deviation.dose-escalation is slower than planned by the genuine
and modified Fibonacci sequence (Figure 2).
The algorithm-based designs tend to be more complex
than the model-based-designs. Most of these new
designs do not use the Fibonacci series. For example,
Simon et al have proposed different designs called accel-
erated titration design, in which the dose doubling is
used until there is one dose-limiting toxicity or two
patients with at least two grade II toxicities at least pos-
sibly related to drug when a 40% increment is used [7].
The Bayesian designs do not use the Fibonacci series
[8,9]. For example, the Bayesian logistic regression
model with escalation with overdose control (EWOC)
uses a model-based approach to determine the potential
unsafe doses. The maximum dose increment may be










1 - - -
2.00 0.80 10 1.82 (0.65)
3.00 0.80 3.33 4.08 (1.65)
4.00 0.97 10.00 9.23 (3.12)
5.32 1.20 33.33 17.61 (4.71)
7.80 0.90 56.25 34.49 (6.89)
11.93 1.86 80.00 67.96 (9.77)
15.78 6.67 128.00 35.64 (5.43)
19.50 13.33 256.00 78.11 (8.69)
23.00 18.00 512.00 133.38 (12.69)
28.89 23.50 1024.00 227.16 (17.85)
38.44 35.83 2048.00 707.43 (29.89)
- - - -













1 - - -
2 2.000 2.000 2.000
3 1.500 1.670 1.500
4 1.667 1.500 1.333
5 1.600 1.333 1.333
6 1.615 1.333 1.333
7 1.619 1.333 1.333
8 1.617 1.333 1.300
9 1.618 1.333 1.350
10 1.618 1.333 1.320
11 1.618 1.333 1.240
12 1.618 1.333 1.250
13 1.618 1.333 -
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there are other safety concerns. These approaches let the
emerging data determine the future dose increment sub-
ject to a cap rather than a fixed algorithm [9]. Based on
the observed toxicity profiles experienced in the trial,
the continual reassessment method estimates the dose-
level closest to the target (eg. 33% of patients presenting
with dose limiting toxicities) and recommends treating
the next patient at that dose level (without skipping dose
levels). This implies an a priori specification of the drug
toxicity profile characterized by a dose-response rela-
tionship for the drug and requires real-time data-
collection, data-management and data-analysis of the
toxicities used for the DLT definitions [8]. This process
may slow down the completion of the trial. PK-guided
designs require a validated, sensitive and specific drug
assay. PK-guided dose-escalation also implies a relation-
ship between plasma drug concentration and toxicity
profile. This process also implies permanent sample col-
lection, shipping, biological analysis and data-analysis.
This may also slow down the trial [6]. As previously
reported [1,2,10], about 50% of contemporary phase I
trials still use the “Fibonacci series”; in our study, PK-
guided dose-escalation or continual reassessement
method are used in 3 and 2% of the trials, respectively.
There are many reasons explaining that Fibonacci series
remains largely used. First, this is one of the first
described methods. This is easy to understand for the
patient, the investigator and the regulatory bodies (such
as Ethics Committee). The Fibonacci series is apparently
cautious with a very progressive dose-escalation. Lastly,
the implementation of this method does not need exten-
sive statistical or biological work as compared to Bayesianapproaches or PK-guided dose-escalation. However, this
method is very rudimentary. Several analyses have demon-
strated that Bayesian approaches, such as Continual Re-
assessment Method or EWOC reduce the number of
patients treated at very low doses far from doses with po-
tential therapeutic effect [2,9,10]. Some authors suggest
than Fibonacci series is preferred when the dose-toxicity
curve in animal toxicology is steep [10].
The main limitation of the present analysis is inherent
to its retrospective nature. This includes a publication
bias that implies a selection of manuscripts issued in
journals with higher impact factors and consequently
the trials with “positive” results.
Conclusion
Modified Fibonacci series remains largely used [1,11].
The actual dose escalation referring to the “modified Fi-
bonacci scheme” is a dose-escalation term close to and
intermediate between the genuine and the “modified Fi-
bonacci” schemes (Figure 2). In practice, however, the
modified Fibonacci sequence, the most popular dose-
escalation guidance scheme in dose-seeking phase I trials
is a term which is too vague and should be avoided. The
precise description of each dose-level in the study report
should be certainly better than the use of this ambiguous
term [5].
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